Eli Lilly releases single-dose vials of Zepbound at half the price of other...
Eli Lilly will begin selling single-dose vials of its drug tirzepatide, marketed as Zepbound for weight loss, and price them at least 50% lower than the list price of all other incretin medicines for...
View ArticleWidening GLP-1 coverage could cost Medicare almost $150B annually, study finds
As Congress considers widening Medicare’s coverage of the burgeoning class of weight loss medications, a new study says further expansion of eligible patients into new indications could cost a pretty...
View ArticleBiopharma companies, BARDA call for more clarity on FDA's new platform tech...
Following the FDA’s May release of long-awaited draft guidance explaining how companies can win designations for certain cell and gene therapy “platform” technologies, companies like Regeneron,...
View ArticleIpsen files another Onivyde lawsuit two weeks after receiving new patent
Two weeks after receiving a new patent on its pancreatic cancer treatment Onivyde, Ipsen has filed another lawsuit against a potential competitor. Ipsen argued on Friday that Conjupro Biotherapeutics’...
View ArticleClik here to view.
Pfizer partners with Flagship genetics startup Quotient on heart and kidney...
Pfizer has struck its second partnership with a Flagship Pioneering startup, working with Quotient Therapeutics to identify genetic mutations that arise by chance throughout life and make individual...
View ArticleClik here to view.
California Institute for Immunology and Immunotherapy gets $120M gift for...
Surgeon Gary Michelson and his wife Alya have donated $120 million to a Los Angeles-based public-private initiative focused on advancing research into immunology and vaccines. The Michelsons’ gift to...
View ArticleClik here to view.
Noetik raises $40M Series A to advance AI ambitions in cancer — with an...
After serving as Pfizer’s top lawyer and now chairing Alnylam’s board, Amy Schulman’s latest biotech bet could be seen as somewhat of a surprise. The managing partner of venture capital firm Polaris...
View ArticleClik here to view.
Bayer partners with RNA startup launched out of Dana-Farber
Even as Bayer continues cutting costs across its conglomerate, it’s still making some small R&D deals to add to its pipeline. On Wednesday, the German multinational pharma and NextRNA Therapeutics...
View ArticleNeurocrine reports Phase 2 schizophrenia data in bid to catch Bristol Myers'...
Neurocrine Biosciences reported Phase 2 schizophrenia data Wednesday morning as it chases Bristol Myers Squibb and AbbVie in an emerging field. The new data showed the low dose of Neurocrine’s program,...
View ArticleNovartis partners with small North Carolina biotech to make its biologics...
Novartis announced a collaboration on Wednesday with a small North Carolina biotech whose technology could help turn more of the Swiss pharma giant’s infused drugs into injections that patients can...
View ArticleNovartis seeks to expand Leqvio into heart disease prevention
Novartis announced Wednesday that Leqvio lowered bad cholesterol levels, compared with a placebo or the cholesterol-lowering drug ezetimibe, in patients at low-to-moderate risk of developing...
View ArticleSpringWorks gets priority review; Botox competitor data; Hyundai's Covid...
SpringWorks scores FDA priority review: The agency accepted mirdametinib’s new drug application and granted it a priority review for the treatment of adult and pediatric patients with neurofibromatosis...
View ArticleFDA warns EyePoint over eye implant manufacturing woes
The FDA has sent EyePoint Pharmaceuticals a warning letter after uncovering manufacturing issues with the company’s eye implant Yutiq. The letter, issued July 12 and published Tuesday, said FDA...
View ArticleSanofi pauses supply of two flu vaccines in China over ‘unexpected...
Sanofi is halting distribution of its two approved flu shots in China due to low potency, and says it won’t meet supply expectations for the products there this flu season. After what it called a...
View ArticleHouse Oversight chair tells PBM CEOs to correct testimonies from July hearing
House Oversight Chair James Comer (R-KY) has told the CEOs of the three major PBMs — CVS Caremark, Express Scripts and Optum Rx — to correct what he’s claiming are contradictions in their statements...
View ArticleRegeneron sues Sandoz to halt biosimilar to its blockbuster eye drug
Regeneron is going after Sandoz in a New Jersey federal court over Sandoz’s recently-approved drug Enzeevu, a biosimilar to Regeneron’s blockbuster eye treatment Eylea. Eylea, which has collected...
View ArticleDelaware high court to review expert testimony in Zantac suits, in win for...
Ten of the plaintiff-chosen experts expected to testify in litigation over whether the heartburn drug Zantac caused cancer will be reviewed by the Delaware Supreme Court, raising the possibility that...
View ArticleUK government partners with pharma on new £400M life science infusion
The new UK Labour government is making one of its first major investments in the biopharma ecosystem, establishing 18 new clinical trial hubs in a joint industry collaboration worth up to £400 million...
View ArticleHow an upstart pharmacy benefit manager has been winning over companies like...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) In a market long dominated by three giants, a different kind of pharmacy benefit manager has been...
View ArticleClik here to view.
BioMarin lays off 225 employees as it cuts spending on gene therapy rollout
BioMarin’s decision to scale back its gene therapy ambitions will result in about 225 employees losing their jobs, the biotech disclosed late Wednesday. The layoffs, which are tied to “organizational...
View Article